Arena Pharmaceuticals Inc (ARNA) Files Form 4 Insider Selling : Christine Anna White Sells 18,728 Shares

Arena Pharmaceuticals Inc (ARNA): Christine Anna White , director of Arena Pharmaceuticals Inc sold 18,728 shares on Jun 13, 2016. The Insider selling transaction was reported by the company on Jun 15, 2016 to the Securities and Exchange Commission. The shares were sold at $1.99 per share for a total value of $37,298.68 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 1, 2015, Randall E Woods (director) sold 76,268 shares at $4.49 per share price.On Mar 18, 2015, Steven W Spector (EVP, General Counsel & Sec) sold 70,000 shares at $5.00 per share price.Also, On Jan 8, 2015, William R Jr Shanahan (SVP & Chief Medical Officer) sold 50,000 shares at $5.49 per share price.

Shares of Arena Pharmaceuticals (ARNA) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.02 points or -1.02% at $1.94 with 10,01,516 shares getting traded. Post opening the session at $1.97, the shares hit an intraday low of $1.93 and an intraday high of $2.02 and the price vacillated in this range throughout the day. The company has a market cap of $472 M and the number of outstanding shares has been calculated to be 24,30,44,670 shares. The 52-week high of Arena Pharmaceuticals is $5.12 and the 52-week low is $1.3.

Arena Pharmaceuticals Money Flow Index Chart

Arena Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Company’s drug BELVIQ (lorcaserin HCl) was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserin’s once-a-day extended release formulation as an aid to smoking cessation in combination with phentermine and other agents for weight management and for other possible indications. The Company’s other drug candidates include ralinepag for vascular diseases APD334 for autoimmune diseases APD371 for pain and fibrotic diseases and temanogrel for thrombotic diseases.

Leave a Reply

Arena Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Arena Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.